BackSolid Biosciences Overview
Solid Biosciences Inc

Solid Biosciences Target Price

See Solid Biosciences's analyst price targets ($20) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$9.58

Average Target Price

$20.00108.8% upside

4 analysts in the last 4 months

High: $26 | Low: $16

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-27Cantor Fitzgerald$26171.4% upsideOpen
2026-08-21Truist FinancialDanielle Brill$20108.8% upsideOpen
2026-05-13Wedbush$1667% upsideOpen
2026-05-13Piper SandlerBiren Amin$1887.9% upsideOpen
2025-12-04NeedhamGil Blum$1667% upsideOpen
2025-11-04Barclays$96.1% downsideOpen
2025-07-21Cantor FitzgeraldCharles Duncan$1667% upsideOpen
2024-06-24Leerink PartnersJoseph Schwartz$1225.3% upsideOpen
2024-05-31Piper SandlerBiren Amin$20108.8% upsideOpen
2024-05-16BarclaysGena Wang$1887.9% upsideOpen
2024-03-13Raymond JamesChristopher Raymond$20108.8% upsideOpen

Solid Biosciences (SLDB) FAQ

Solid Biosciences's target price stands at $20. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $20 for SLDB implies 108.8% upside versus today's price ($9.58). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Solid Biosciences's target price evolved across reporting periods, while the comparison chart places SLDB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Solid Biosciences's reading of $20 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.